William T. Symonds
Chairman of Scientific Advisory BoardDr. William T. Symonds III, Pharm.D., also known as Bill, serves as an Advisor at Forty51 Advisors AG. He is CEO at Enzyvant. Dr. Symonds serves as a Director at Resolution Therapeutics Limited. He serves as Member of Product Advisory Board of Lokavant, Inc. since April 2023. He has been the Chief Executive Officer of Altavant Sciences, Inc. since August 2018 and serves as its Director. Dr. Symonds serves as Chairman of Scientific Advisory Board at Arbutus Biopharma Corporation since October 18, 2018. Dr. Symonds was Chief Development Officer of Arbutus Biopharma Corporation since March 2015 until 2018. Dr. Symonds had been Senior Vice President of Clinical Research at Roivant Sciences, Inc., since May 2014 Dr. Symonds served as Chief Development Officer at Roivant Sciences, Inc. Prior to that, he served as Vice-President of Liver Disease Therapeutic Area at Gilead Sciences, Inc. from February 2012 to April 2014. He served as Senior Vice President of Clinical Pharmacology and Translational Medicine at Pharmasset, Inc. from 2007 to January 2012. at Pharmasset, Inc. He served as a Vice President of Clinical Pharmacology of Gilead Pharmasset LLC from January 24, 2007, to January 2012. He served as Senior Advisor of OnCore since November 2014. From 1993 to 2007, he held various positions of increasing responsibility at GlaxoSmithKline, most recently as Director, Antiviral Clinical Pharmacology and Discovery Medicine. He Led the development of compounds for hepatitis B virus and hepatitis C virus infection, most notably Sovaldi® for hepatitis C and Contributed to new drug approvals for Ziagen®, Agenerase® and Epzicom® during his tenure at GlaxoSmithKline. He is a seasoned drug development professional with extensive experience in the clinical development of multiple new drug candidates from phase 1 to phase 4. He had been an Executive Director of Arbutus Biopharma Corporation since March 4, 2015, until October 18, 2018. He also served as a Director of Arbutus Inc. from August 2014 to March 2015. He served as a Director of OnCore Biopharma, Inc. since August 2014 and served as its Chief Development Officer since March 2015. Dr. Symonds received his Doctorate of Pharmacy from Campbell University in North Carolina and he completed a Fellowship in Clinical Pharmacokinetics focusing on anti-infective pharmacology at the Clinical Pharmacokinetics Laboratory at Millard Fillmore Hospital in Buffalo, New York.
Positions
- Company NameArbutus Biopharma CorporationStock CodeABUSPositionChairman of Scientific Advisory Board
